Navigation Links
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Date:2/4/2008

Children's Oncology Group Report Shows the Addition of L-MTP-PE to Chemotherapy Reduced the Risk of Death by 30% in Osteosarcoma Patients

IRVINE, Calif., Feb. 4 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced the Journal of Clinical Oncology (JCO) has published findings from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133), entitled "Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival - A Report from the Children's Oncology Group." The landmark clinical trial, which is the largest study completed in this disease was a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG).

The COG's findings were based on long-term follow up of 662 patients with newly diagnosed non-metastatic osteosarcoma treated in the Phase 3 trial and demonstrated that the addition of L-MTP-PE to chemotherapy following surgery resulted in statistically superior Overall Survival (OS) the first stated aim of the study.

In the past two decades, there have been no treatment advances for patients with osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

"L-MTP-PE in combination with chemotherapy has demonstrated a significant long-term overall survival advantage in the largest Phase 3 clinical trial completed in patients with osteosarcoma," said Dr. Paul Meyers, vice chair, department of pediatrics at Memorial Sloan-Kettering Cancer Center and principal investigator of the Phase 3 trial. "These results are encouraging for children and young adults with osteosarcoma, considering the lack of progress for these patients in the last 20 years."

The JCO publication
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... AMBOY, N.J. , Sept. 29, 2014 ... accept customer service inquiries via Twitter, the social media ... to Tweet inquiries and issues related to customer service ... Twitter,s ubiquitous use and its accessibility from any ... Medical Center to better serve its patients and community. ...
(Date:9/29/2014)... , Sept. 29, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API), today announced that ... official site visit by the China Food & ... (GMP) certification. In early September 2014, ...
(Date:9/29/2014)... Sept. 29, 2014  Diplomat, the nation,s largest ... has been named chief information officer. As ... the information technology department while being responsible for ... and external partnerships. Prior to joining ... in the development of technology architectures and organizational ...
Breaking Medicine Technology:@myrbmc: Healthcare Customer Service Support in 140 Characters or Less 2TPI's QLF Completes GMP site inspection by CFDA 2TPI's QLF Completes GMP site inspection by CFDA 3Diplomat names Stephen S. Brown chief information officer 2
... Dec. 6, 2011  Therakos, Inc., a pioneer in ... immune modulation therapy, today announced that the first ... clinical study evaluating the use of the company,s ... moderate-to-severe chronic Graft-versus-Host Disease (GvHD). An estimated 15,000 ...
... Dec. 6, 2011 Mobile patient monitoring innovator ... to collaborate with Qualcomm Life Inc., a wholly ... execute a home health monitoring initiative that integrates ... Qualcomm 2net™Platform. The initial focus of AirStrip,s initiative ...
Cached Medicine Technology:First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 2First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease 3AirStrip Technologies Announces Home Health Collaboration With Qualcomm Life 2AirStrip Technologies Announces Home Health Collaboration With Qualcomm Life 3
(Date:9/30/2014)... New York, NY (PRWEB) September 30, 2014 ... an award-winning managed IT solutions firm based in ... contract to deploy CRA’s Manage360° solution to transform, ... NYC-based Nonprofit Organization (NPO) who is a leading ... become healthy, productive, and self sufficient. The ...
(Date:9/30/2014)... 2014 All on Four dental ... persons who have received dental implants to vigilant in ... post. , The post, which can be found at ... if they don’t brush and floss diligently, they could ... their natural teeth: the bone will deteriorate and the ...
(Date:9/30/2014)... September 30, 2014 Signet Puerto ... based in San Juan, Puerto Rico, leverages RamSoft’s ... , Nivia Souffront, site Administrator for Signet ... “We are excited to bring in PowerServer RIS/PACS/PM ... patient care and physician satisfaction while reducing our ...
(Date:9/30/2014)... Westminster, Maryland (PRWEB) September 30, 2014 3M ... of acrylic very high bond tapes. 3M 5906 , ... 3M 5909 are conformable VHBs which help create the ... acrylic foam tapes are used for bonding to difficult surfaces ... , 3M VHBs 5906, 5907, 5908, and 5905 are designed ...
(Date:9/30/2014)... Doctors often order breast ultrasounds as a follow-up, after a ... are done at a specialized medical imaging center, such as ... The Center for Diagnostic Imaging is now offering breast ultrasounds ... find ultrasounds to be more comfortable as they can be ... perfectly still. , “We realize that receiving abnormal ...
Breaking Medicine News(10 mins):Health News:CRA Awarded Managed Services Contract for Large NYC Nonprofit 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Breast Ultrasounds Are a Comfortable and Convenient Option for Patients and Referring Doctors 2
... bacteria, scientists had been able to use light as ... cavity. ,The dental samples obtained from patients suffering ... to 520nm). The light had selectively killed oral black-pigmented ... samples obtained from patients. Medium strength light had killed ...
... team from the University of Western Ontario had found out that ... ,The study used a robot arm to show how ... the video of this learning process was shown to a group, ... the people in the video. Moreover people who learned the same ...
... scientists, consuming food with high glycemic index have been //linked ... which had spanned 16.6 years and observed the incidence of ... is much significant for women who are past their menopause. ... foods that have simple carbohydrates and sugars like refined flour, ...
... can lead to mothers being less emotionally involved with ... a new study done by researchers of Pennsylvania State ... pregnancy and childbirth was previously related to post-partum depression ... The new study suggests that bonding with their newborns ...
... the second phase of testing of the vaccine for ... cancers and 90% of genital warts. ,277 women ... months and regularly had gynecological examination, cervicovaginal sampling for ... to HPV. , ,The results showed the incidence ...
... the pattern of rising early from bed in the mornings ... ,The behavior is called familial advanced sleep phase ... is said to be the phenotype of the gene PER2. ... the phosphorylation site in the casein kinase I (CKI) domain ...
Cached Medicine News:
... Micro Anchor is the smallest, strongest ... flexibility in placement into even the ... with 3-0 or 4-0 ETHIBOND EXCEL ... or cutting swaged needles. The kit ...
... a threaded titanium anchor, specifically ... The anchor features wide threads ... optimize bone purchase, as well ... prevent suture binding. Fastin RC ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... Proxis features 'proximal protection' -- providing ... removal, even in vessels with side branches. ... to use. It does not require the ... removal of embolic debris. ,Proxis is ...
Medicine Products: